NCT02315326 trial: what clinicians have said so far
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
- NCT02315326 ↗
- Completed
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02315326 (ibrutinib plus methotrexate plus rituximab; ibrutinib plus methotrexate plus rituximab plus procarbazine in primary or secondary central nervous system lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02315326 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- Ibrutinib; HD- Methotrexate (MTX); Rituximab + HD- Methotrexate (MTX); procarbazine
- Arms
- Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL · Experimental
- Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL · Experimental
- Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL · Experimental
- Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL · Experimental
- Enrollment
- 93
- Primary outcomes
- define the Maximum Tolerated Dose (MTD) of ibrutinib (phase I)
- progression free survival (phase II)
- define the Maximum Tolerated Dose (MTD) of ibrutinib in combination with high-dose Methotrexate (HD-MTX)
- Sponsor
- Memorial Sloan Kettering Cancer Center with Pharmacyclics LLC., Janssen Biotech, Inc.
- Start
- Dec 8, 2014
- Primary completion
- Jan 28, 2026
- Results posted
- No
- Registry record
- NCT02315326 · updated Feb 2, 2026
Publications
linked from the registry- Krebs S, Mauguen A, Yildirim O, Hatzoglou V, Francis JH, Schaff LR, Mellinghoff IK, Schoder H, Grommes C. Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3940-3950. doi: 10.1007/s00259-021-05386-0. Epub 2021 May 8. PubMed 33966087
- Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19. PubMed 30567753